I'm not sure it's just about the sample size.
BP have paid billions for promising pre-clinical drugs in the neurodegenerative space.
I wonder how much PAA being an ASX listed company impacts on BP's interesting in acquisitions.
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow), page-54
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $94.81M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $156.9K | 801.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 823726 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 378863 | 10 |
View Market Depth
| Last trade - 15.53pm 01/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |